Newsroom

Sight Sciences Announces Publication of Favorable Two-Year Outcomes of Standalone Use of the OMNI® Surgical System in Mild to Moderate Open-Angle Glaucoma

Pioneering the Development of the Standalone MIGS Market, this Real-world data published in Clinical Ophthalmology show the safety, efficacy, and durability of effect of OMNI for use in a standalone procedure to reduce intraocular pressure and medication burden

read more +
Sight Sciences Reports Second Quarter 2021 Financial Results

MENLO PARK, Calif., August 12, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and...

read more +
Sight Sciences to Report Second Quarter 2021 Financial Results on August 12, 2021

MENLO PARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the second quarter 2021 after the market close...

read more +
Sight Sciences Announces Pricing of Initial Public Offering

Sight Sciences Announces Pricing of Initial Public Offering

read more +
Sight Sciences Announces Substantial Crossover Raise

Funds will be used to continue clinical and commercial acceleration

read more +
Sight Sciences Announces Positive Interim Clinical Results from Prospective, Multicenter Trial of the OMNI Surgical System in Open Angle Glaucoma

Data presented at the Women in Ophthalmology 2020 Virtual Summer Symposium

read more +
Sight Sciences Announces First Patients Enrolled in ORION: A Prospective, Multicenter Clinical Trial of the OMNI Surgical System in Pseudophakic, Mild-to-Moderate Glaucoma Patients

Trial to Provide Surgeons with Prospective, Standalone Clinical Data on Microinvasive Glaucoma Surgery

read more +
Sight Sciences Appoints Donald J. Zurbay to Company’s Board of Directors

Highly accomplished industry executive brings financial and operational expertise to innovative eye care company

read more +